BioMarin Pharmaceutical

BioMarin Pharmaceutical Financials

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

BioMarin Pharmaceutical financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

$69.9

2024-10-29

Market Capitalization

$13.3 B

2024-10-29

Revenue

$3.2 B

FY, 2025

CreditSafe Score

Score changed on Jun 07, 2026

Premium Content only available in Craft’s Intelligence Portal

View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.

Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.

Learn more

Financial Statements

USD	FY, 2010	FY, 2011	FY, 2012	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017	FY, 2018	FY, 2019	FY, 2020	FY, 2021	FY, 2022	FY, 2023	FY, 2024	FY, 2025
Revenue	376.3M	441.4M	500.7M	548.5M	751.0M	889.9M	1.1B	1.3B	1.5B	1.7B	1.9B	1.8B	2.1B	2.4B	2.9B	3.2B
Revenue growth, %					36.9%	18.5%	25.5%
Cost of goods sold	70.3M	84.0M	91.8M	95.7M	129.8M	152.0M	209.6M	241.8M	315.3M	359.5M	524.3M	470.5M	483.7M	514.9M	580.2M	717.4M
Gross profit	306.0M	357.3M	408.9M	452.7M	621.3M	737.9M	907.2M	1.1B	1.2B	1.3B	1.3B		1.6B	1.9B	2.3B	2.5B
Gross profit margin, %	81.3%	81.0%	81.7%	82.5%	82.7%	82.9%	81.2%	81.6%	78.9%	78.9%	71.8%		76.9%	78.7%	79.7%	77.7%
General and administrative expense	151.7M	175.4M	198.2M				476.6B	554.3M	604.4M	680.9M	737.7M	759.4M	854.0M	937.3M	1.0B	1.2B
Operating expense total	305.4M	391.2M	519.1M				1.1T	1.1B	1.3B	1.4B	1.4B	1.5B	1.5B	1.7B	1.8B	2.1B
Depreciation and amortization																19.4M
EBIT	544.0K	(33.9M)	(110.2M)	(156.0M)	(92.9M)	(110.7M)	(803.4M)	(14.7M)	(123.5M)	(100.5M)	(36.8M)	(82.3M)	149.6M	158.1M	484.2M	409.5M
EBIT margin, %	0.1%	-7.7%	-22.0%	-28.4%	-12.4%	-12.4%	-71.9%	-1.1%	-8.3%	-5.9%	-2.0%		7.1%	6.5%	17.0%	12.7%
Investment income	(3.0M)	(2.4M)	(1.2M)					(1.3M)	(553.0K)	(587.0K)	(6.0K)
Interest income	4.1M	2.9M	2.6M	3.1M	5.9M	4.5M	7.5B	14.9M	22.8M	22.7M	16.6M	10.5M	18.0M	58.3M	74.9M	74.9M
Interest expense	10.3M	8.3M	7.6M	10.4M	36.6M	38.2M	39.5M							17.3M	10.4M
Pre tax profit	(21.5M)	(43.6M)	(118.3M)	(176.5M)	(124.9M)	(154.7M)	(831.0M)	(35.9M)	(142.7M)	(94.8M)	(42.3M)	(75.3M)	149.6M	188.6M	541.8M	482.5M
Income tax expense	(227.3M)	10.2M	(3.9M)	(150.0K)	9.1M	17.1M	(200.8M)	81.2M	(65.5M)	(71.0M)	(901.4M)	(11.3M)	8.0M	20.9M	114.9M	133.6M
Net Income	205.8M	(53.8M)	(114.3M)	(176.4M)	(134.0M)	(171.8M)	(630.2M)	(117.0M)	(77.2M)	(23.8M)	859.1M	(64.1M)	141.6M	167.6M	426.9M	348.9M
EPS													0.8	0.9	2.2	1.8

BioMarin Pharmaceutical Financials

CreditSafe Score

Financial Statements

Footer menu

Product

Solutions

Resources

Company